Dr. James Wheless, MD
NPI: 1659337855
Total Payments
$1.6M
2024 Payments
$176,337
Companies
40
Transactions
2,244
Medicare Patients
66
Medicare Billing
$6,910
Payment Breakdown by Category
Other$954,559 (58.0%)
Consulting$283,572 (17.2%)
Travel$219,616 (13.3%)
Research$139,778 (8.5%)
Food & Beverage$40,630 (2.5%)
Education$8,477 (0.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $806,494 | 425 | 49.0% |
| Consulting Fee | $283,572 | 133 | 17.2% |
| Travel and Lodging | $219,616 | 821 | 13.3% |
| Unspecified | $139,778 | 93 | 8.5% |
| Honoraria | $132,565 | 65 | 8.1% |
| Food and Beverage | $40,630 | 685 | 2.5% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $15,500 | 8 | 0.9% |
| Education | $8,477 | 14 | 0.5% |
Payments by Type
General
$1.5M
2,151 transactions
Research
$139,778
93 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| EISAI INC. | $339,383 | 440 | $0 (2022) |
| UCB, Inc. | $215,262 | 388 | $0 (2024) |
| Neurelis, Inc. | $181,613 | 170 | $0 (2024) |
| Sunovion Pharmaceuticals Inc. | $142,493 | 280 | $0 (2020) |
| SK Life Science, Inc. | $112,653 | 120 | $0 (2024) |
| LivaNova USA, Inc. | $111,001 | 149 | $0 (2024) |
| JAZZ PHARMACEUTICALS INC. | $94,765 | 129 | $0 (2024) |
| NEUROPACE, INC. | $74,617 | 94 | $0 (2024) |
| Greenwich Biosciences, Inc. | $68,777 | 101 | $0 (2021) |
| Supernus Pharmaceuticals, Inc. | $54,058 | 78 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $176,337 | 246 | JAZZ PHARMACEUTICALS INC. ($49,339) |
| 2023 | $161,780 | 250 | UCB, Inc. ($52,919) |
| 2022 | $265,730 | 289 | Neurelis, Inc. ($104,219) |
| 2021 | $144,583 | 207 | SK Life Science, Inc. ($36,349) |
| 2020 | $137,173 | 142 | Neurelis, Inc. ($21,884) |
| 2019 | $265,502 | 365 | EISAI INC. ($95,644) |
| 2018 | $316,010 | 479 | Eisai Inc. ($124,038) |
| 2017 | $179,515 | 266 | Eisai Inc. ($82,929) |
All Payment Transactions
2,244 individual payment records from CMS Open Payments — Page 1 of 90
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Consulting Fee | Cash or cash equivalent | $947.50 | General |
| Category: Antiepileptic | ||||||
| 12/18/2024 | Neurelis, Inc. | VALTOCO (Drug) | Consulting Fee | Cash or cash equivalent | $2,965.00 | General |
| Category: EPILEPSY | ||||||
| 12/17/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | In-kind items and services | $18.69 | General |
| Category: Neurology | ||||||
| 12/08/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Consulting Fee | Cash or cash equivalent | $4,164.00 | General |
| Category: Antiepileptic | ||||||
| 12/08/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $165.56 | General |
| 12/08/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Food and Beverage | In-kind items and services | $75.54 | General |
| Category: Antiepileptic | ||||||
| 12/06/2024 | H. Lundbeck A S | — | Travel and Lodging | Cash or cash equivalent | $425.36 | General |
| 12/06/2024 | H. Lundbeck A S | — | Travel and Lodging | In-kind items and services | $268.17 | General |
| 12/06/2024 | H. Lundbeck A S | — | Travel and Lodging | In-kind items and services | $268.17 | General |
| 12/06/2024 | H. Lundbeck A S | — | Travel and Lodging | In-kind items and services | $240.98 | General |
| 12/06/2024 | Neurelis, Inc. | VALTOCO (Drug) | Food and Beverage | In-kind items and services | $103.25 | General |
| Category: EPILEPSY | ||||||
| 12/06/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Food and Beverage | In-kind items and services | $70.00 | General |
| Category: Antiepileptic | ||||||
| 12/05/2024 | Neurelis, Inc. | VALTOCO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,265.00 | General |
| Category: EPILEPSY | ||||||
| 11/26/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,490.00 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Travel and Lodging | In-kind items and services | $800.87 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Travel and Lodging | In-kind items and services | $700.00 | General |
| Category: NEUROLOGY | ||||||
| 11/22/2024 | JAZZ PHARMACEUTICALS INC. | EPIDIOLEX (Drug) | Food and Beverage | In-kind items and services | $182.07 | General |
| Category: NEUROLOGY | ||||||
| 11/21/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Travel and Lodging | Cash or cash equivalent | $263.98 | General |
| Category: Antiepileptic | ||||||
| 11/21/2024 | UCB, Inc. | Fintepla (Drug) | Food and Beverage | Cash or cash equivalent | $95.94 | General |
| Category: Neurology | ||||||
| 11/21/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Food and Beverage | In-kind items and services | $87.14 | General |
| Category: Antiepileptic | ||||||
| 11/21/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Food and Beverage | In-kind items and services | $72.43 | General |
| Category: Antiepileptic | ||||||
| 11/21/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Travel and Lodging | Cash or cash equivalent | $44.32 | General |
| Category: Antiepileptic | ||||||
| 11/21/2024 | BIOCODEX, INC. | DIACOMIT (Drug) | Travel and Lodging | Cash or cash equivalent | $24.76 | General |
| Category: Antiepileptic | ||||||
| 11/21/2024 | UCB, Inc. | Fintepla (Drug) | Travel and Lodging | Cash or cash equivalent | $19.80 | General |
| Category: Neurology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| AN OPEN-LABEL, SINGLE-DOSE, PHARMACOKINETICS STUDY OF VALTOCO WITH OPEN-LABEL SAFETY PERIOD IN PEDIATRIC SUBJECTS WITH EPILEPSY | Neurelis, Inc. | $52,561 | 6 |
| Post Approval Study | NEUROPACE, INC. | $33,204 | 60 |
| RNS Adolescents with Epilepsy study | NEUROPACE, INC. | $14,000 | 4 |
| Retro Chart Review for under 18 patients study | NEUROPACE, INC. | $12,350 | 3 |
| RESEARCH RELATED PUBLICATION SUPPORT | NOVARTIS PHARMACEUTICALS CORPORATION | $5,236 | 2 |
| RNS System Post-Approval Study in Epilepsy | NEUROPACE, INC. | $4,727 | 6 |
| A critical evaluation of midazolam nasal spray for the treatment of patients with seizure clusters | UCB, Inc. | $4,600 | 2 |
| A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy and Safety of Lacosamide as Adjunctive T | UCB, Inc. | $2,300 | 1 |
| Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit A double-blind, randomized, placebo-controlled trial | UCB, Inc. | $2,300 | 1 |
| Safety and efficacy of midazolam nasal spray for the treatment of intermittent bouts of increased seizure activity in the epilepsy monitoring unit: A double-blind, randomized, placebo-controlled trial | UCB, Inc. | $2,300 | 1 |
| Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters - a randomized, double-blind, placebo-controlled trial | UCB, Inc. | $2,300 | 1 |
| An Open-Label Safety Study of USL261 in the Outpatient Treatment of Subjects With Seizure Clusters | UCB, Inc. | $840.00 | 2 |
| Fenfluramine Responder Analysis and Numbers Needed to Treat: Post-Hoc Pooled Analysis of Two Phase 3 Studies in Dravet Syndrome | UCB, Inc. | $820.00 | 1 |
| Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters post hoc analysis of an open-label extension trial | UCB, Inc. | $820.00 | 1 |
| Return to full baseline functionality after repeated intermittent use of midazolam nasal spray in patients with seizure clusters: post hoc analysis of an open-label extension trial | UCB, Inc. | $820.00 | 1 |
| Response Study | NEUROPACE, INC. | $600.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 1 | 18 | 22 | $9,020 | $2,460 |
| 2022 | 1 | 18 | 20 | $8,200 | $1,904 |
| 2021 | 1 | 16 | 18 | $7,380 | $1,380 |
| 2020 | 1 | 14 | 18 | $7,380 | $1,166 |
Total Patients
66
Total Services
78
Medicare Billing
$6,910
Procedure Codes
4
All Medicare Procedures & Services
4 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 18 | 22 | $9,020 | $2,460 | 27.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 18 | 20 | $8,200 | $1,904 | 23.2% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Office | 2021 | 16 | 18 | $7,380 | $1,380 | 18.7% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Office | 2020 | 14 | 18 | $7,380 | $1,166 | 15.8% |
About Dr. James Wheless, MD
Dr. James Wheless, MD is a Neurology with Special Qualifications in Child Neurology healthcare provider based in Memphis, Tennessee. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/25/2006. The National Provider Identifier (NPI) number assigned to this provider is 1659337855.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. James Wheless, MD has received a total of $1.6M in payments from pharmaceutical and medical device companies, with $176,337 received in 2024. These payments were reported across 2,244 transactions from 40 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($806,494).
As a Medicare-enrolled provider, Wheless has provided services to 66 Medicare beneficiaries, totaling 78 services with total Medicare billing of $6,910. Data is available for 4 years (2020–2023), covering 4 distinct procedure/service records.
Ad
Practice Information
- Specialty Neurology with Special Qualifications in Child Neurology
- Location Memphis, TN
- Active Since 04/25/2006
- Last Updated 06/28/2018
- Taxonomy Code 2084N0402X
- Entity Type Individual
- NPI Number 1659337855
Products in Payments
- Fycompa (Drug) $322,155
- VALTOCO (Drug) $181,613
- Fintepla (Drug) $156,423
- APTIOM (Drug) $142,493
- EPIDIOLEX (Drug) $94,765
- XCOPRI (Drug) $92,828
- Epidiolex (Drug) $68,777
- VNS Therapy (Device) $56,546
- OXTELLAR XR (Drug) $53,977
- RNS System (Device) $53,428
- Vimpat (Drug) $40,290
- ACTHAR (Biological) $33,923
- VNS THERAPY SENTIVA MODEL 1000 GENERATOR (Device) $28,221
- RNS Neurostimulator Kit (Device) $21,189
- Briviact (Drug) $20,678
- VNS - Sentiva (Device) $17,680
- ONFI (Drug) $17,523
- DIACOMIT (Drug) $17,520
- ZTALMY (Drug) $16,750
- Banzel (Drug) $15,069
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neurology with Special Qualifications in Child Neurology Doctors in Memphis
Sarah Weatherspoon, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $73,463
Neurology with Special Qualifications in Child Neurology $73,463
Dr. Ankita Ghosh, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $29,000
Neurology with Special Qualifications in Child Neurology $29,000
Dr. Kathleen Nicole Jalandoni, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $15,490
Neurology with Special Qualifications in Child Neurology $15,490
Daniel Guillen Mendoza, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $10,755
Neurology with Special Qualifications in Child Neurology $10,755
Dr. Basanagoud Mudigoudar, M.d, M.D
Neurology with Special Qualifications in Child Neurology — Payments: $2,434
Neurology with Special Qualifications in Child Neurology $2,434
Dr. Amy Mcgregor, Md, MD
Neurology with Special Qualifications in Child Neurology — Payments: $1,805
Neurology with Special Qualifications in Child Neurology $1,805